Request a FREE Sample of our FcRn Binding Kit!Request a FREE Sample of our FcRn Binding Kit!
Limited Edition Golden Llama is here! Check out how you can get one. Limited Edition Golden Llama is here! Check out how you can get one.
Request a FREE sample of our GMP products! Request a FREE sample of our GMP products!
Captured Human RANK, Mouse IgG2a Fc Tag, low endotoxin (Cat. No. RAK-H5251) on CM5 chip via Anti-Mouse antibodies surface can bind Human TNFSF11, Fc Tag (Cat. No. RAL-H5265) with an affinity constant of 0.574 nM as determined in a SPR assay (Biacore T200) (Routinely tested).
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Narlumosbart | JMT-103 | Approved | Shanghai Jmt-Bio Inc | 津立生 | Mainland China | Giant Cell Tumor of Bone | Shanghai Jmt-Bio Inc | 2023-09-05 | Solid tumours; Bone metastases; Osteoporosis; Bone Diseases; Osteoporosis, Postmenopausal; Hypercalcemia; Neoplasms; Multiple Myeloma; Giant Cell Tumor of Bone; Glucocorticoid-induced osteoporosis | Details |
Denosumab biosimilar (Mabwell) | 9-MW-0311; 9MW0321; 9-MW0321; 9MW-0321; 9-MW-0321; TK-006; MW-032; MW-031; 9MW0311; 9-MW0311; 9MW-0311 | Approved | Jiangsu T-Mab Bio-Pharmaceuticals Co Ltd | 迈利舒, 迈卫健, MAIWEIJIAN, MAILISHU | Mainland China | Osteoporosis, Postmenopausal | Jiangsu T-Mab Bio-Pharmaceuticals Co Ltd | 2023-03-28 | Bone metastases; Solid tumours; Osteoporosis; Osteoporosis, Postmenopausal; Breast Neoplasms; Giant Cell Tumor of Bone; Bone Neoplasms | Details |
Denosumab biosimilar (Qilu Pharma) | QL-1206 | Approved | Qilu Pharmaceutical Co Ltd | 鲁可欣 | Mainland China | Osteoporosis, Postmenopausal | Qilu Pharmaceutical Co Ltd | 2023-09-28 | Solid tumours; Bone metastases; Osteoporosis, Postmenopausal | Details |
Denosumab biosimilar (Boan Biopharma/Luye) | LY-01011; BA-1102; BA-6101; LY-06006 | Approved | Luye Pharma Group Ltd | Mainland China | Osteoporosis, Postmenopausal | Shandong Boan Biotechnology Co Ltd | 2022-11-10 | Bone metastases; Solid tumours; Osteoporosis; Osteoporosis, Postmenopausal; Neoplasms; Multiple Myeloma; Giant Cell Tumor of Bone; Bone Neoplasms; Neoplasm Metastasis | Details | |
Denosumab | NSC-744010; AMG-162 | Approved | Amgen Inc | Prolia, Xgeva, Pralia, Ranmark, 普罗力 | EU | Osteoporosis, Postmenopausal | Amgen Europe Bv | 2010-05-26 | Lymphoma; Multiple Myeloma; Prostatic Neoplasms, Castration-Resistant; Feeding and Eating Disorders; Breast Neoplasms; Prostatic Neoplasms; Giant Cell Tumors; Arthropathy, Neurogenic; Osteogenesis Imperfecta; Osteosarcoma; Giant Cell Tumor of Bone; Breast Diseases; Bone Neoplasms; Fractures, Bone; Bone Cysts, Aneurysmal; Lung Neoplasms; Osteoblastoma; Granuloma, Giant Cell; Thyroid Neoplasms; Lymphoma, Non-Hodgkin; Glucocorticoid-induced osteoporosis; Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Fibroma; Crohn Disease; Anorexia Nervosa; Fibrous Dysplasia of Bone; Kidney Neoplasms; Solid tumours; Cataract; Hematologic Neoplasms; Endocrine Gland Neoplasms; Head and Neck Neoplasms; Hematopoietic stem cell transplantation (HSCT); Bone Diseases, Metabolic; Osteoporosis; Carcinoma; Pain; Parathyroid Neoplasms; Bone metastases; Osteoporosis, Postmenopausal; Smoldering Multiple Myeloma; Colonic Neoplasms; Hypercalcemia; Neoplasms; Chondroblastoma; Kidney Diseases; Carcinoma, Ovarian | Details |
Denosumab biosimilar(Reliance Life Sciences) | R-TPR-045 | Approved | Reliance Life Sciences | DenosuRel | India | Osteoporosis, Postmenopausal; Bone metastases | Reliance Life Sciences | 2022-02-01 | Bone metastases; Osteoporosis, Postmenopausal | Details |
Denosumab biosimilar (Sandoz) | GP-2411 | Approved | Novartis Pharma Ag, Sandoz | Jubbonti®, Wyost® | United States | Osteoporosis; Osteoporosis, Postmenopausal; Glucocorticoid-induced osteoporosis | Sandoz Inc, Sandoz | 2024-03-05 | Osteoporosis; Osteoporosis, Postmenopausal; Glucocorticoid-induced osteoporosis | Details |
Narlumosbart | JMT-103 | Approved | Shanghai Jmt-Bio Inc | 津立生 | Mainland China | Giant Cell Tumor of Bone | Shanghai Jmt-Bio Inc | 2023-09-05 | Solid tumours; Bone metastases; Osteoporosis; Bone Diseases; Osteoporosis, Postmenopausal; Hypercalcemia; Neoplasms; Multiple Myeloma; Giant Cell Tumor of Bone; Glucocorticoid-induced osteoporosis | Details |
Denosumab biosimilar (Mabwell) | 9-MW-0311; 9MW0321; 9-MW0321; 9MW-0321; 9-MW-0321; TK-006; MW-032; MW-031; 9MW0311; 9-MW0311; 9MW-0311 | Approved | Jiangsu T-Mab Bio-Pharmaceuticals Co Ltd | 迈利舒, 迈卫健, MAIWEIJIAN, MAILISHU | Mainland China | Osteoporosis, Postmenopausal | Jiangsu T-Mab Bio-Pharmaceuticals Co Ltd | 2023-03-28 | Bone metastases; Solid tumours; Osteoporosis; Osteoporosis, Postmenopausal; Breast Neoplasms; Giant Cell Tumor of Bone; Bone Neoplasms | Details |
Denosumab biosimilar (Qilu Pharma) | QL-1206 | Approved | Qilu Pharmaceutical Co Ltd | 鲁可欣 | Mainland China | Osteoporosis, Postmenopausal | Qilu Pharmaceutical Co Ltd | 2023-09-28 | Solid tumours; Bone metastases; Osteoporosis, Postmenopausal | Details |
Denosumab biosimilar (Boan Biopharma/Luye) | LY-01011; BA-1102; BA-6101; LY-06006 | Approved | Luye Pharma Group Ltd | Mainland China | Osteoporosis, Postmenopausal | Shandong Boan Biotechnology Co Ltd | 2022-11-10 | Bone metastases; Solid tumours; Osteoporosis; Osteoporosis, Postmenopausal; Neoplasms; Multiple Myeloma; Giant Cell Tumor of Bone; Bone Neoplasms; Neoplasm Metastasis | Details | |
Denosumab | NSC-744010; AMG-162 | Approved | Amgen Inc | Prolia, Xgeva, Pralia, Ranmark, 普罗力 | EU | Osteoporosis, Postmenopausal | Amgen Europe Bv | 2010-05-26 | Lymphoma; Multiple Myeloma; Prostatic Neoplasms, Castration-Resistant; Feeding and Eating Disorders; Breast Neoplasms; Prostatic Neoplasms; Giant Cell Tumors; Arthropathy, Neurogenic; Osteogenesis Imperfecta; Osteosarcoma; Giant Cell Tumor of Bone; Breast Diseases; Bone Neoplasms; Fractures, Bone; Bone Cysts, Aneurysmal; Lung Neoplasms; Osteoblastoma; Granuloma, Giant Cell; Thyroid Neoplasms; Lymphoma, Non-Hodgkin; Glucocorticoid-induced osteoporosis; Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Fibroma; Crohn Disease; Anorexia Nervosa; Fibrous Dysplasia of Bone; Kidney Neoplasms; Solid tumours; Cataract; Hematologic Neoplasms; Endocrine Gland Neoplasms; Head and Neck Neoplasms; Hematopoietic stem cell transplantation (HSCT); Bone Diseases, Metabolic; Osteoporosis; Carcinoma; Pain; Parathyroid Neoplasms; Bone metastases; Osteoporosis, Postmenopausal; Smoldering Multiple Myeloma; Colonic Neoplasms; Hypercalcemia; Neoplasms; Chondroblastoma; Kidney Diseases; Carcinoma, Ovarian | Details |
Denosumab biosimilar(Reliance Life Sciences) | R-TPR-045 | Approved | Reliance Life Sciences | DenosuRel | India | Osteoporosis, Postmenopausal; Bone metastases | Reliance Life Sciences | 2022-02-01 | Bone metastases; Osteoporosis, Postmenopausal | Details |
Denosumab biosimilar (Sandoz) | GP-2411 | Approved | Novartis Pharma Ag, Sandoz | Jubbonti®, Wyost® | United States | Osteoporosis; Osteoporosis, Postmenopausal; Glucocorticoid-induced osteoporosis | Sandoz Inc, Sandoz | 2024-03-05 | Osteoporosis; Osteoporosis, Postmenopausal; Glucocorticoid-induced osteoporosis | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Denosumab biosimilar (Intas Biopharmaceuticals) | Phase 3 Clinical | Intas Biopharmaceuticals | Osteoporosis, Postmenopausal | Details | |
Denosumab biosimilar(Shanghai Hansoh) | HS-20090; HS-20090-2 | Phase 3 Clinical | Shanghai Hansoh Biomedical Co Ltd, Jiangsu Hansoh Pharmaceutical Group Co Ltd | Bone metastases; Solid tumours; Neoplasms; Osteoporosis, Postmenopausal; Bone Diseases; Hypercalcemia; Multiple Myeloma; Giant Cell Tumor of Bone; Nutritional and Metabolic Diseases | Details |
TVB-009 | TVB-009 | Phase 3 Clinical | Teva Pharmaceutical Industries Ltd | Osteoporosis, Postmenopausal | Details |
Denosumab biosimilar (Henlius ) | HLX-14; HLX14 | Phase 3 Clinical | Shanghai Henlius Biotech Inc | Osteoporosis, Postmenopausal | Details |
CMAB807 | CMAB-807; CMAB807X | Phase 3 Clinical | Shanghai Biomabs Pharmaceuticals Co Ltd, Shanghai Maitai Yabo Biotechnology Co Ltd | Osteoporosis, Postmenopausal | Details |
Recombinant human anti-RANKL momoclonal antibody (Qilu Pharmaceutical) | Phase 3 Clinical | Qilu Pharmaceutical Co Ltd | Osteoporosis, Postmenopausal; Neoplasms | Details | |
Denosumab biosimilar (AryoGen) | Phase 3 Clinical | Aryogen Biopharma | Osteoporosis | Details | |
Denosumab biosimilar(Curateq Biologics) | BP-16 | Phase 3 Clinical | CuraTeQ Biologics Pvt Ltd | Osteoporosis, Postmenopausal | Details |
Denosumab biosimilar(Enzene Biosciences) | ENZ-215 | Phase 3 Clinical | Enzene Biosciences Ltd | Osteoporosis, Postmenopausal | Details |
Denosumab biosimilar(Alvotech Swiss) | AVT-03 | Phase 3 Clinical | Alvotech Swiss Ag | Osteoporosis, Postmenopausal | Details |
Denosumab biosimilar(Mabxience) | Phase 3 Clinical | Mabxience Sa | Osteoporosis, Postmenopausal | Details | |
Denosumab biosimilar (Hualan Biological Engineering) | Phase 3 Clinical | Hualan Genetic Engineering Co Ltd | Solid tumours; Bone metastases; Osteoporosis, Postmenopausal | Details | |
RGB-14-P | RGB-14-P | Phase 3 Clinical | Gedeon Richter Plc | Osteoporosis, Postmenopausal | Details |
Denosumab biosimilar(Fresenius Kabi) | FKS-518 | Phase 3 Clinical | Fresenius Kabi Swissbiosim Gmbh | Osteoporosis, Postmenopausal | Details |
Denosumab biosimilar (Samsung Bioepis) | SB-16 | Phase 3 Clinical | Samsung Bioepis Co Ltd | Osteoporosis, Postmenopausal | Details |
Denosumab biosimiliar (Celltrion) | CT-P41 | Phase 3 Clinical | Celltrion Inc | Osteoporosis, Postmenopausal | Details |
KP-46 | KP-46; FFC-11; LX-001; AP-002 | Phase 2 Clinical | University Of Heidelberg, Meram | Solid tumours | Details |
LZM-004 | LZM-004 | Phase 1 Clinical | Livzon(Group) Pharmaceutical Factory | Bone metastases | Details |
Recombinant human anti-RANKL antibody (Innovent Biologics) | IBI-307 | Phase 1 Clinical | Innovent Biologics(Suzhou) Co Ltd | Osteoporosis | Details |
GB-223 | GB-223 | Phase 1 Clinical | Genor Biopharma Co Ltd | Solid tumours; Bone metastases; Osteoporosis, Postmenopausal; Bone Neoplasms; Giant Cell Tumor of Bone | Details |
MV-088 | MV-088 | Phase 1 Clinical | Kpc Pharmaceuticals Inc | Osteoporosis, Postmenopausal | Details |
Recombinant anti-RANKL monoclonal antibody(Jiangsu Pacific-Meinuoke) | Phase 1 Clinical | Jiangsu Pacific-Meinuoke Bio-Pharmaceutical Co Ltd | Osteoporosis, Postmenopausal | Details | |
Recombinant human anti-RANKL antibody (Hisun Pharma) | HS629 | Phase 1 Clinical | Zhejiang Hisun Pharmaceutical Co Ltd | Bone metastases; Solid tumours | Details |
Denosumab biosimilar (Intas Biopharmaceuticals) | Phase 3 Clinical | Intas Biopharmaceuticals | Osteoporosis, Postmenopausal | Details | |
Denosumab biosimilar(Shanghai Hansoh) | HS-20090; HS-20090-2 | Phase 3 Clinical | Shanghai Hansoh Biomedical Co Ltd, Jiangsu Hansoh Pharmaceutical Group Co Ltd | Bone metastases; Solid tumours; Neoplasms; Osteoporosis, Postmenopausal; Bone Diseases; Hypercalcemia; Multiple Myeloma; Giant Cell Tumor of Bone; Nutritional and Metabolic Diseases | Details |
TVB-009 | TVB-009 | Phase 3 Clinical | Teva Pharmaceutical Industries Ltd | Osteoporosis, Postmenopausal | Details |
Denosumab biosimilar (Henlius ) | HLX-14; HLX14 | Phase 3 Clinical | Shanghai Henlius Biotech Inc | Osteoporosis, Postmenopausal | Details |
CMAB807 | CMAB-807; CMAB807X | Phase 3 Clinical | Shanghai Biomabs Pharmaceuticals Co Ltd, Shanghai Maitai Yabo Biotechnology Co Ltd | Osteoporosis, Postmenopausal | Details |
Recombinant human anti-RANKL momoclonal antibody (Qilu Pharmaceutical) | Phase 3 Clinical | Qilu Pharmaceutical Co Ltd | Osteoporosis, Postmenopausal; Neoplasms | Details | |
Denosumab biosimilar (AryoGen) | Phase 3 Clinical | Aryogen Biopharma | Osteoporosis | Details | |
Denosumab biosimilar(Curateq Biologics) | BP-16 | Phase 3 Clinical | CuraTeQ Biologics Pvt Ltd | Osteoporosis, Postmenopausal | Details |
Denosumab biosimilar(Enzene Biosciences) | ENZ-215 | Phase 3 Clinical | Enzene Biosciences Ltd | Osteoporosis, Postmenopausal | Details |
Denosumab biosimilar(Alvotech Swiss) | AVT-03 | Phase 3 Clinical | Alvotech Swiss Ag | Osteoporosis, Postmenopausal | Details |
Denosumab biosimilar(Mabxience) | Phase 3 Clinical | Mabxience Sa | Osteoporosis, Postmenopausal | Details | |
Denosumab biosimilar (Hualan Biological Engineering) | Phase 3 Clinical | Hualan Genetic Engineering Co Ltd | Solid tumours; Bone metastases; Osteoporosis, Postmenopausal | Details | |
RGB-14-P | RGB-14-P | Phase 3 Clinical | Gedeon Richter Plc | Osteoporosis, Postmenopausal | Details |
Denosumab biosimilar(Fresenius Kabi) | FKS-518 | Phase 3 Clinical | Fresenius Kabi Swissbiosim Gmbh | Osteoporosis, Postmenopausal | Details |
Denosumab biosimilar (Samsung Bioepis) | SB-16 | Phase 3 Clinical | Samsung Bioepis Co Ltd | Osteoporosis, Postmenopausal | Details |
Denosumab biosimiliar (Celltrion) | CT-P41 | Phase 3 Clinical | Celltrion Inc | Osteoporosis, Postmenopausal | Details |
KP-46 | KP-46; FFC-11; LX-001; AP-002 | Phase 2 Clinical | University Of Heidelberg, Meram | Solid tumours | Details |
LZM-004 | LZM-004 | Phase 1 Clinical | Livzon(Group) Pharmaceutical Factory | Bone metastases | Details |
Recombinant human anti-RANKL antibody (Innovent Biologics) | IBI-307 | Phase 1 Clinical | Innovent Biologics(Suzhou) Co Ltd | Osteoporosis | Details |
GB-223 | GB-223 | Phase 1 Clinical | Genor Biopharma Co Ltd | Solid tumours; Bone metastases; Osteoporosis, Postmenopausal; Bone Neoplasms; Giant Cell Tumor of Bone | Details |
MV-088 | MV-088 | Phase 1 Clinical | Kpc Pharmaceuticals Inc | Osteoporosis, Postmenopausal | Details |
Recombinant anti-RANKL monoclonal antibody(Jiangsu Pacific-Meinuoke) | Phase 1 Clinical | Jiangsu Pacific-Meinuoke Bio-Pharmaceutical Co Ltd | Osteoporosis, Postmenopausal | Details | |
Recombinant human anti-RANKL antibody (Hisun Pharma) | HS629 | Phase 1 Clinical | Zhejiang Hisun Pharmaceutical Co Ltd | Bone metastases; Solid tumours | Details |
This web search service is supported by Google Inc.